Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | QDPR | P09417 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2884886 | 0.98 | HTR2C (0.49) | PLGHTR2CQDPRSLC18A3SIGMAR1 | |
| SCHEMBL21475943 | 0.88 | QDPR (0.41) | QDPRSLC18A3SIGMAR1HTR6 | |
| SCHEMBL629693 | 0.81 | ESR2 (0.44) | QDPR | |
| SCHEMBL12975679 | 0.78 | PLG (0.45) | PLGHTR2CQDPRSLC18A3SIGMAR1 | |
| SCHEMBL16977251 | 0.77 | REN (0.47) | RENKCNH2 | |
| SCHEMBL12975670 | 0.76 | QDPR (0.41) | PLGHTR2CQDPRSLC18A3SIGMAR1 | |
| SCHEMBL23442948 | 0.74 | SLC6A2 (0.49) | HTR2CQDPRSLC18A3SIGMAR1KCNH2 | |
| SCHEMBL29891558 | 0.74 | SLC6A2 (0.49) | HTR2CQDPRSLC18A3SIGMAR1KCNH2 | |
| SCHEMBL5584815 | 0.74 | QDPR (0.46) | HTR2CQDPRSLC18A3SIGMAR1HTR6 | |
| SCHEMBL629587 | 0.74 | IKBKE (0.38) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | PLG 4351/4885HTR2C 90/4885QDPR 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.